Trial Profile
Garenoxacin to Prevent Febrile Neutropenia in Chemotherapy for Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Garenoxacin (Primary)
- Indications Febrile neutropenia; Lung cancer
- Focus Therapeutic Use
- 11 Dec 2014 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 04 Aug 2014 New trial record